JP6672255B2 - Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法 - Google Patents

Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法 Download PDF

Info

Publication number
JP6672255B2
JP6672255B2 JP2017500822A JP2017500822A JP6672255B2 JP 6672255 B2 JP6672255 B2 JP 6672255B2 JP 2017500822 A JP2017500822 A JP 2017500822A JP 2017500822 A JP2017500822 A JP 2017500822A JP 6672255 B2 JP6672255 B2 JP 6672255B2
Authority
JP
Japan
Prior art keywords
mmol
compound
nmr
phenyl
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017500822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017520588A (ja
JP2017520588A5 (enExample
Inventor
ダン セオドレスク
ダン セオドレスク
マイケル ウェンペ
マイケル ウェンペ
デイビッド ロス
デイビッド ロス
チャオ ヤン
チャオ ヤン
フィリップ リーガン
フィリップ リーガン
Original Assignee
ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト
ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト, ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト filed Critical ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト
Publication of JP2017520588A publication Critical patent/JP2017520588A/ja
Publication of JP2017520588A5 publication Critical patent/JP2017520588A5/ja
Application granted granted Critical
Publication of JP6672255B2 publication Critical patent/JP6672255B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017500822A 2014-07-10 2015-07-10 Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法 Expired - Fee Related JP6672255B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462022946P 2014-07-10 2014-07-10
US62/022,946 2014-07-10
PCT/US2015/040021 WO2016007905A1 (en) 2014-07-10 2015-07-10 Anti-cancer compounds target ral gtpases and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020036345A Division JP7102012B2 (ja) 2014-07-10 2020-03-04 Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法

Publications (3)

Publication Number Publication Date
JP2017520588A JP2017520588A (ja) 2017-07-27
JP2017520588A5 JP2017520588A5 (enExample) 2018-08-16
JP6672255B2 true JP6672255B2 (ja) 2020-03-25

Family

ID=55064987

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017500822A Expired - Fee Related JP6672255B2 (ja) 2014-07-10 2015-07-10 Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法
JP2020036345A Active JP7102012B2 (ja) 2014-07-10 2020-03-04 Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020036345A Active JP7102012B2 (ja) 2014-07-10 2020-03-04 Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法

Country Status (9)

Country Link
US (4) US10202397B2 (enExample)
EP (2) EP3686202A1 (enExample)
JP (2) JP6672255B2 (enExample)
KR (3) KR20170018084A (enExample)
CN (1) CN106604731B (enExample)
AU (2) AU2015287567A1 (enExample)
CA (1) CA2954560C (enExample)
IL (1) IL249959A0 (enExample)
WO (1) WO2016007905A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020105195A (ja) * 2014-07-10 2020-07-09 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10646475B2 (en) 2015-03-10 2020-05-12 The Trustees Of Princeton University SHMT inhibitors
US10077273B2 (en) 2016-09-14 2018-09-18 The Trustees Of Princeton University SHMT inhibitors
CN109305972B (zh) * 2018-09-27 2021-07-09 广州医科大学 一种二氢吡喃并吡唑类化合物及其制备方法和应用
EP3766544A1 (en) * 2019-07-18 2021-01-20 Centre Hospitalier Regional Universitaire de Lille Novel pyrazolone derivatives as pd-1/pd-l1 interaction inhibitors
CA3199138A1 (en) * 2020-11-18 2022-05-27 Texas Tech University System Therapies for cancer using small molecules that bind to and inhibit ral interacting proteins
CN114765064A (zh) * 2021-01-14 2022-07-19 南京天顶星医药科技有限公司 一种靶向RalA-GDP蛋白的药物的虚拟筛选方法
AU2022272475A1 (en) 2021-05-10 2023-10-05 Novalum S.a. Cathode current collector bar of an aluminium production cell
CN114632147B (zh) * 2021-11-09 2024-04-30 南京大学 人类受试者心肌病的治疗

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4555396A (en) 1982-12-22 1985-11-26 Eastman Kodak Company Use of pyrylium and thiapyrylium compounds as biological stains
US5750550A (en) 1995-09-15 1998-05-12 Sanofi 2-(pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3 (2H)-One 1, 1-dioxides and compositions and method of use thereof
JPH10279480A (ja) 1997-04-07 1998-10-20 Mitsubishi Chem Corp 皮膚組織障害の予防・治療剤
US6143471A (en) 1998-03-10 2000-11-07 Mitsubishi Paper Mills Limited Positive type photosensitive composition
WO2000040749A2 (en) 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
WO2005020784A2 (en) * 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
CA2533803A1 (en) * 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
KR20080015123A (ko) 2005-05-25 2008-02-18 다나베 미츠비시 세이야꾸 가부시키가이샤 피라졸론 유도체를 포함하는 의약
US7826982B2 (en) 2005-07-29 2010-11-02 Children's Hospital Medical Center Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE
KR20080040032A (ko) 2005-09-02 2008-05-07 티보텍 파마슈티칼즈 리미티드 Ｈｃｖ 저해제로서의 벤조디아제핀
EP1957474A4 (en) 2005-11-04 2011-08-24 Harvard College SYNTHESIS OF FTSZ HEMMERN
US20070203224A1 (en) 2006-01-09 2007-08-30 University Of Southern California Small-molecules for treating cancer and abnormal cell proliferation disorders
WO2008143894A2 (en) 2007-05-14 2008-11-27 Dana-Farber Cancer Institute, Inc. Phosphorylated rala
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011010715A1 (ja) * 2009-07-24 2011-01-27 国立大学法人 東京大学 Ｐr－Ｓｅｔ７阻害剤
WO2011035143A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Methods and compositions for inhibiting rho-mediated diseases and conditions
US8673913B2 (en) * 2009-11-13 2014-03-18 Case Western Reserve University SHP-2 phosphatase inhibitor
US20120214824A1 (en) 2010-12-08 2012-08-23 Bradley Tait Proteostasis regulators
US9200046B2 (en) * 2011-06-29 2015-12-01 Cornell University Reporter system for high throughput screening of compounds and uses thereof
EP2793881B1 (en) * 2011-12-21 2018-10-31 The Regents of the University of Colorado Anti-cancer compounds targeting ral gtpase
US20150011411A1 (en) 2011-12-21 2015-01-08 THE REGENTS OF THE UNIVERSITY OF COLORADO a body corporation Biomarkers of cancer
WO2013152313A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
WO2013182472A1 (en) * 2012-06-06 2013-12-12 Basf Se Pyrazolopyrans having herbicidal and pharmaceutical properties
CN103910737B (zh) * 2014-03-25 2016-08-17 浙江师范大学 手性的1,4-二氢吡喃(2,3-c)吡唑衍生物及其合成方法和应用
WO2016007905A1 (en) * 2014-07-10 2016-01-14 The Regents Of The University Of Colorado, A Body Corporate Anti-cancer compounds target ral gtpases and methods of using the same
WO2016205460A1 (en) * 2015-06-16 2016-12-22 Nantbioscience, Inc. Polycyclic derivatives targeting ral gtpases and their therapeutical applications

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020105195A (ja) * 2014-07-10 2020-07-09 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法
JP7102012B2 (ja) 2014-07-10 2022-07-19 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法

Also Published As

Publication number Publication date
AU2015287567A1 (en) 2017-02-16
JP2017520588A (ja) 2017-07-27
KR20170018084A (ko) 2017-02-15
JP7102012B2 (ja) 2022-07-19
CN106604731A (zh) 2017-04-26
US20170204112A1 (en) 2017-07-20
WO2016007905A1 (en) 2016-01-14
US11472812B2 (en) 2022-10-18
EP3686202A1 (en) 2020-07-29
EP3166609B1 (en) 2020-03-11
CA2954560C (en) 2021-12-28
USRE48557E1 (en) 2021-05-18
KR20200034824A (ko) 2020-03-31
EP3166609A4 (en) 2017-12-27
AU2020277293A1 (en) 2021-01-07
EP3166609A1 (en) 2017-05-17
IL249959A0 (en) 2017-03-30
CA2954560A1 (en) 2016-01-14
JP2020105195A (ja) 2020-07-09
KR102093848B1 (ko) 2020-03-30
CN106604731B (zh) 2021-05-18
AU2020277293B2 (en) 2021-10-21
US10676480B2 (en) 2020-06-09
KR20190022929A (ko) 2019-03-06
US10202397B2 (en) 2019-02-12
US20190135824A1 (en) 2019-05-09
US20200255442A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
JP6672255B2 (ja) Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法
JP6473330B2 (ja) ＲａｌＧＴＰアーゼを標的とする抗がん化合物及びその使用方法
AU2025200238A1 (en) KAT6 inhibitor methods and combinations for cancer treatment
JP5411393B2 (ja) ピラゾロキノリン類
US11560373B2 (en) Compounds and their use as PDE4 activators
EP4667055A2 (en) Kat6 inhibitor methods and combinations for cancer treatment
HK40088938A (zh) 用於癌症治疗的kat6抑制剂方法及组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170301

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190305

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200304

R150 Certificate of patent or registration of utility model

Ref document number: 6672255

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees